Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–789.
   Web of Science ®Google Scholar
• Yagawa Y, Tanigawa K, Kobayashi Y, et al. Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery. J Cancer Metastasis Treatment. 2017;3(10):218–230.
   Google Scholar
• Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–370.
   PubMed Web of Science ®Google Scholar
• Khodabakhsh F, Behdani M, Rami A, et al. Single-domain antibodies or nanobodies: a class of next-generation antibodies. Int Rev Immunol. 2018;37(6):316–322.
   PubMed Web of Science ®Google Scholar
• Alirahimi E, Kazemi-Lomedasht F, Shahbazzadeh D, et al. Nanobodies as novel therapeutic agents in envenomation. Biochim Biophys Acta Gen Subj. 2018;1862(12):2955–2965.
   PubMed Web of Science ®Google Scholar
• Xu M-Y, Xu X-H, Chen G-Z, et al. Production of a human single-chain variable fragment antibody against esophageal carcinoma. World J Gastroenterol. 2004;10(18):2619–2623.
   PubMed Web of Science ®Google Scholar
• Roshan R, Naderi S, Behdani M, et al. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy. Mol Immunol. 2021;129:70–77.
   PubMed Web of Science ®Google Scholar
• Naderi S, Roshan R, Ghaderi H, et al. Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis. Mol Immunol. 2020;128:56–63.
   PubMed Web of Science ®Google Scholar
• Baharlou R, Tajik N, Behdani M, et al. An antibody fragment against human delta-like ligand-4 for inhibition of cell proliferation and neovascularization. Immunopharmacol Immunotoxicol. 2018;40(5):368–374.
   PubMed Web of Science ®Google Scholar
• Spasevska I, Duong MN, Klein C, et al. Advances in bispecific antibodies engineering: novel concepts for immunotherapies. J Blood Disord Transfus. 2015;6:243.
   Google Scholar
• Mohseni N, Roshan R, Naderi S, et al. In vitro combination therapy of pathologic angiogenesis using anti-vascular endothelial growth factor and anti-neuropilin-1 nanobodies. Iran J Basic Med Sci. 2020;23(10):1335–1339.
   PubMed Web of Science ®Google Scholar
• Karami E, Naderi S, Roshan R, et al. Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies. Cancer Chemother Pharmacol. 2022;89(2):165–172.
   PubMed Web of Science ®Google Scholar
• Bagheri M, Babaei E, Shahbazzadeh D, et al. Development of a recombinant camelid specific diabody against the heminecrolysin fraction of hemiscorpius lepturus scorpion. Toxin Rev. 2017;36(1):7–11.
   Web of Science ®Google Scholar
• Safi M, Ahmed H, Al-Azab M, et al. PD-1/PDL-1 inhibitors and cardiotoxicity; molecular, etiological and management outlines. J Adv Res. 2021;29:45–54.
   PubMed Web of Science ®Google Scholar
• Makuku R, Khalili N, Razi S, et al. Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy. J Immunol Res. 2021;2021:6661406.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 2014;20(4):256–261.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou S, Yang F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008–1019.
   PubMed Web of Science ®Google Scholar
• Markham A. Atezolizumab: first global approval. Drugs. 2016;76(12):1227–1232.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
   PubMed Web of Science ®Google Scholar
• Itatani Y, Kawada K, Yamamoto T, et al. Resistance to anti-angiogenic therapy in cancer—alterations to anti-VEGF pathway. Int J Mol Sci. 2018;19(4):1232.
   PubMed Web of Science ®Google Scholar
• Khodabakhsh F, Muyldermans S, Behdani M, et al. Liposomal delivery of vascular endothelial growth factor/receptors and their inhibitors. J Drug Target. 2020;28(4):379–385.
   PubMed Web of Science ®Google Scholar
• Ahadi M, Ghasemian H, Behdani M, et al. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor. J Immunotoxicol. 2019;16(1):34–42.
   PubMed Web of Science ®Google Scholar
• Sadeghi A, Behdani M, Muyldermans S, et al. Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization. Drug Test Anal. 2020;12(1):92–100.
   PubMed Web of Science ®Google Scholar
• Oghalaie A, Mahboudi F, Rahimi-Jamnani F, et al. Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate. Iran J Basic Med Sci. 2022;25(3):313–319.
   PubMed Web of Science ®Google Scholar
• Karami E, Sabatier J-M, Behdani M, et al. A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis. J Enzyme Inhib Med Chem. 2020;35(1):1233–1239.
   PubMed Web of Science ®Google Scholar
• Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods. 1987;100(1–2):173–179.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gu T, Tian X, et al. PD-1/PD-L1 inhibitor 1 (PDI-1) as an immune-checkpoint inhibitor for NSCLC and melanoma immunotherapy. Front Immunol. 2021;12:1372.
   Web of Science ®Google Scholar
• Kamba T, McDonald D. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–1795.
   PubMed Web of Science ®Google Scholar
• Zhang J-Y, Yan Y-Y, Li J-J, et al. PD-1/PD-L1 based combinational cancer therapy: icing on the cake. Front Pharmacol. 2020;11:722.
   PubMed Web of Science ®Google Scholar
• Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9(3):34.
   Web of Science ®Google Scholar
• Salvador J, Vilaplana L, Marco M. Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem. 2019;411(9):1703–1713.
   PubMed Web of Science ®Google Scholar
• Ling W-L, Lua W-H, Gan SK-E. Sagacity in antibody humanization for therapeutics, diagnostics and research purposes: considerations of antibody elements and their roles. Antib Ther. 2020;3(2):71–79.
   PubMedGoogle Scholar